Tilray seeks Nasdaq extension amid share price compliance issues

Published 14/08/2025, 12:06
Tilray seeks Nasdaq extension amid share price compliance issues

NEW YORK/LEAMINGTON, Ontario - Cannabis and consumer goods company Tilray Brands, Inc. (NASDAQ:TLRY; TSX:TLRY), currently trading at $1.25 with a market capitalization of $1.37 billion, has applied for an extension to regain compliance with Nasdaq’s minimum share price requirements, according to a press release issued Thursday.

The company is considering several options to address its capital structure, including a potential stockholder-approved reverse stock split to maintain its Nasdaq listing.

CEO Irwin Simon noted that Tilray’s stock has recently appreciated following President Trump’s review of cannabis rescheduling, which he suggested reflects investor confidence in the company’s diversified global platform.

"Tilray has multiple options to meet Nasdaq’s requirements, and with this extension request, we are giving the market additional time to demonstrate its confidence in our long-term strategy," Simon said in the statement.

Nasdaq listing rules typically require listed companies to maintain a minimum bid price of $1.00 per share. Companies failing to meet this requirement for 30 consecutive business days receive notification and are generally given 180 calendar days to regain compliance.

Tilray describes itself as a global lifestyle consumer packaged goods company operating across cannabis, beverage, and wellness sectors with a presence in Canada, the United States, Europe, Australia, and Latin America.

The company’s portfolio includes over 40 brands in more than 20 countries, according to the press release.

In other recent news, Tilray Inc. reported its fourth-quarter 2025 financial results, revealing a mixed performance. The company achieved earnings per share of $0.02, which exceeded analyst expectations of -$0.02. However, Tilray’s revenue fell short, recording $224.5 million compared to the projected $247.02 million, a 9.12% miss. Despite the revenue shortfall, Jefferies maintained its Buy rating for Tilray, setting a price target of $1.50. Jefferies attributed the revenue miss to factors such as soft beer demand and delays in cannabis shipments. In a broader industry context, Tilray’s stock, along with other cannabis companies, saw gains after reports that President Trump is considering reclassifying marijuana as a less dangerous drug. This potential regulatory shift could significantly impact the cannabis sector. These developments highlight the dynamic nature of the cannabis industry, with both challenges and opportunities on the horizon.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.